(UroToday.com) The optimal management of patients with complete response after first-line chemotherapy remains unsettled with guidelines recommending either surveillance or retroperitoneal lymph node dissection (RPLND). At the 2021 American Society of Clinical Oncology (ASCO) Annual Meeting, Dr. Jennifer King and colleagues presented results of their study assessing long-term outcomes from a large dataset of patients managed with surveillance after achieving complete response to first-line chemotherapy.